Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 29, 2009

Avacta Takes Over TheraGenetics to Expand into Clinical Diagnostics

  • Avacta acquired TheraGenetics, a firm focused on diagnostics related to CNS disorders, in a cash-and-stock transaction. TheraGenetics’ tests are being designed to determine patient response to treatment as well as drug side effects.

    Avacta develops detection and analysis technology aimed primarily at the pharmaceutical and healthcare markets and has lately entered the field of clinical diagnostics. The takeover of TheraGenetics thus gives it a stronger position in personalized medicine.

    TheraGenetics is developing pharmacogenetic tests for schizophrenia, depression, bipolar disorder, Alzheimer’s, and ADHD.  “We have made tremendous progress in our efforts to link genes to specific CNS disorders and advance the development of our diagnostic tests,” remarks Richard Kivel, CEO of TheraGenetics.

    ---

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »